CTLA4 and neoplasm: In agreement with previous observations,42 we also observed changes in the phenotype of tumor-infiltrating Tregs upon treatment with anti-CTLA-4 mAb 9D9, suggesting that anti-CTLA-4 therapy reduces the activation, stability, and function of Tregs.